Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
64Cu-RAX301
- Development stage
- Unknown
- Lead developer
- Beijing Junlikang Biotechnology
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
64Cu-RAX301 is a next-generation radiopharmaceutical PET tracer targeting prostate-specific membrane antigen (PSMA). It consists of the RAX301 ligand labeled with the positron-emitting radioisotope copper-64 (64Cu). Designed to overcome the limitations of shorter-lived tracers like 68Ga-PSMA-11, 64Cu-RAX301 exhibits ultra-high binding affinity (sub-picomolar Kd) and extended biochemical stability, allowing for delayed imaging up to 24 hours post-injection. This extended imaging window, combined with high tumor-to-background contrast and minimal urinary interference in the pelvic region, enhances the detection of small metastatic lesions and lymph node metastases in patients with prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC).
- Other names
- Copper-64 RAX301Copper64 RAX301Copper 64 RAX301
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 64Cu-RAX301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 64Cu-RAX301.